Compare DigitalOcean Holdings Inc (DOCN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs BIO-TECHNE Corp — how do they compare? DigitalOcean Holdings Inc trades at $125.66 (market cap $14.57B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: DigitalOcean Holdings Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and BIO-TECHNE Corp for 63 Days on average.
| DOCN | TECH | |
|---|---|---|
Market Cap | $14.57B | $11.36B |
Volume | 2,261,786 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $181.29 | $72.61 |
52-Week Low | $37.30 | $43.31 |
Typical Hold Time | 43 Days | 63 Days |
Enterprise Value | $15.33B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong technical support at $126 and resistance at $130. The company shows robust revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive to $259M. Recent AI-focused product launches including Agent Droplets and Managed Agents position the company for continued growth in cloud services.
Despite high valuation multiples (P/E 57.85, P/S 14.34), analyst consensus remains bullish with a $172.73 price target representing 36% upside. Key risks include capital intensity from expansion and high debt levels, while institutional accumulation and consistent earnings beats support the growth narrative.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
